阿达木单抗治疗成人克罗恩病或溃疡性结肠炎临床试验的长期安全性
该研究汇总16项2/3期及3/3b期试验及其开放标签扩展研究,评估阿达木单抗治疗成人克罗恩病(CD)与溃疡性结肠炎(UC)的长期安全性。CD组累计暴露4145患者年、UC组3397患者年,不良事件、严重不良事件及恶性肿瘤发生率与既往分析相似,恶性肿瘤标准化发病比与一般人群相近,未见新的安全性信号。
要点
- CD与UC中阿达木单抗总体不良事件、严重不良事件及恶性肿瘤发生率与既往分析相似
- CD恶性肿瘤标准化发病比1.45(95%CI 0.90-2.22),UC为1.36(95%CI 0.84-2.07),与一般人群相似
- 脱髓鞘疾病不常见,CD为0.1事件/100患者年,UC为<0.1事件/100患者年
核心结论
- 中重度活动性克罗恩病或溃疡性结肠炎患者继续使用阿达木单抗具有可接受的安全性,未见新的安全性信号。
研究设计与样本
- 汇总2/3期及3/3b期试验与开放标签扩展研究共16项,成人克罗恩病N=3606、溃疡性结肠炎N=1739,累计暴露分别为4145和3397患者年。
- 治疗中出现的不良事件定义为首次给药至末次给药后70天或2015年12月31日,采用MedDRA-v18.1编码,发生率以事件/100患者年表示。
主要发现
- CD中阿达木单抗任何不良事件发生率为60.8%-65.1%(依剂量而定),安慰剂为71.5%;UC中分别为53.5%-54.8%和56.1%。
- 任何不良事件发生率CD为605事件/100患者年、UC为361事件/100患者年;严重不良事件CD为36.1、UC为18.9事件/100患者年;恶性肿瘤CD为1.2、UC为1.0事件/100患者年。
- 机会性感染表观发生率经近期MedDRA调整排除口腔念珠菌病和结核后,CD降至0.3、UC降至0.2事件/100患者年。
- 恶性肿瘤标准化发病比CD为1.45(95%CI 0.90-2.22)、UC为1.36(95%CI 0.84-2.07),与一般人群相似。
- 脱髓鞘疾病不常见,CD为0.1事件/100患者年,UC为<0.1事件/100患者年。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Adalimumab is used to treat moderate to severe Crohn's disease (CD) and ulcerative colitis (UC) when conventional therapies fail. AIM: To update long-term adalimumab safety from CD and UC trials; the previous report was CD only, 3160 patients/3402 patient-years (PYs). METHODS: Treatment-emergent adverse events (AEs; first dose to 70 days after last dose/December 31, 2015) in adults in phase 2/3 and 3/3b trials and open-label extensions were coded using Medical Dictionary for Regulatory Activities (MedDRA-v18.1). Rates were assessed as events/100 (E/100 PYs). RESULTS: The database (16 trials; CD, N = 3606; UC, N = 1739) represented 4145 and 3397 PYs of exposure, respectively. For CD, incidences of any AEs with adalimumab were 60.8%-65.1%, depending on dose, and 71.5% with placebo; for UC, the incidences were 53.5%-54.8% and 56.1%, respectively. Rates of any AEs (CD, 605 E/100 PYs; UC, 361 E/100 PYs), serious AEs (CD, 36.1 E/100 PYs; UC, 18.9 E/100 PYs), and malignancies (CD, 1.2 E/100 PYs; UC, 1.0 E/100 PYs) were similar between current and prior analyses. Apparent rate of opportunistic infections was lowered to 0.3 and 0.2 E/100 PYs for CD and UC, respectively, by recent MedDRA changes excluding oral candidiasis and tuberculosis. Standardised incidence ratios for malignancies were similar to the general population (CD, 1.45 [95% CI, 0.90-2.22]; UC, 1.36 [95% CI, 0.84-2.07]). Demyelinating disorders were uncommon (CD, 0.1 E/100 PYs; UC, <0.1 E/100 PYs). CONCLUSIONS: Patients with moderately to severely active Crohn's disease or ulcerative colitis continued to experience acceptable safety with adalimumab, without new safety signals.
引用
- Colombel JF, Sandborn WJ, Reinisch W, et al. Long-term safety of adalimumab in clinical trials in adult patients with Crohn's disease or ulcerative colitis. Aliment Pharmacol Ther. 2017. PMID: 29159817. doi:10.1111/apt.14420
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。